Author Interviews, Infections, NEJM, STD / 06.03.2025
NEJM: Treating Male Partners Reduces Recurrence Rate of Bacterial Vaginosis
MedicalResearch.com Interview with:
[caption id="attachment_66982" align="alignleft" width="150"]
Dr. Vodstrcil[/caption]
Lenka Vodstrcil PhD
Senior Research Fellow
Deputy Head, Genital Microbiota and Mycoplasma Group
President, Sexual Health Society of Victoria
Associate Editor, Sexually Transmitted Infections
School of Translational Medicine, FMNHS, Monash University
Melbourne Sexual Health Centre, The Alfred Hospital
Melbourne School of Population & Global Health, University of Melbourne
[caption id="attachment_66983" align="alignleft" width="150"]
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
Dr. Vodstrcil[/caption]
Lenka Vodstrcil PhD
Senior Research Fellow
Deputy Head, Genital Microbiota and Mycoplasma Group
President, Sexual Health Society of Victoria
Associate Editor, Sexually Transmitted Infections
School of Translational Medicine, FMNHS, Monash University
Melbourne Sexual Health Centre, The Alfred Hospital
Melbourne School of Population & Global Health, University of Melbourne
[caption id="attachment_66983" align="alignleft" width="150"]
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
Prof. Michaelides[/caption]
Professor Michel Michaelides BSc MB BS MD(Res) FRCOphth FACS
Professor of Ophthalmology and Consultant Ophthalmic Surgeon
UCL Institute of Ophthalmology and Moorfields Eye Hospital
MedicalResearch.com: What is the background for this study?
Prof. Mihaylova[/caption]
Borislava Mihaylova, DPhil
Associate Professor & Senior Health Economist
Nuffield Department of Population Health, University of Oxford,
UK & Professor of Health Economics
Wolfson Institute of Population Health
Queen Mary University of London, UK
MedicalResearch.com: What is the background for this study?
Response: Despite high risks of heart disease and stroke in people over 70 years old and high need for preventive treatment such as statins, fewer older people use statins [compared to middle-aged people]. This, at least in part, is likely due to fewer older people, particularly those without previous heart attacks and strokes, included in the randomized studies of statin treatment. This has led to more limited evidence among them with larger uncertainty. Thus, we set to re-examine the value of statin treatment using the latest evidence and contemporary population data.
Dr. Davis[/caption]
Esa M. Davis, M.D., M.P.H , F.A.A.F.P
Professor of Medicine and Family and Community Medicine
Associate Vice President of Community Health and
Senior Associate Dean of pPopulation Health and Community Medicine
University of Maryland School of Medicine
Dr. Davis joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Iron is important to overall health, and people need more iron when they are pregnant. This can make pregnant people at increased risk for iron deficiency, which can progress to anemia and cause complications for both moms and their babies. After reviewing the latest available research, the Task Force found that there is not enough evidence on whether pregnant people who do not have signs or symptoms of iron deficiency or anemia should be screened—or take iron supplements—to improve their health or the health of their baby.
Dr. Oliva[/caption]
Azahara Oliva PhD
Assistant Professor
Department of Neurobiology and Behavior
Cornell University
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The background is that we knew for a while now that neurons work hard to consolidate into memories each experience that we have during the day. But at the same time, it is known that sleep restore activity of our body and physiology. How was that possible? How can the neurons in our brain "work hard" during the time that we are supposed to be restoring our vitals? We found that in between their hard work, during sleep, our neurons take "breaks of activity" so our brain can build memories with precision.
Ben Petrazzini[/caption]
Ben Omega Petrazzini, B.Sc.
Associate Bioinformatician